Saturday 17 October 2026
Export KURA’s income statement to Excel — free account
Kura Oncology, Inc.
KURA Healthcare Biotechnology
Kura Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $67.5 million, up 25.2% from fiscal 2024. In the quarter to June 2026, revenue grew 36.5%, EPS fell 2.67%, free cash flow fell 109.1% and total debt rose 1.76%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
9.08
0.62
−6.39%
Follow KURA
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
0.00 | 13.50 | 10.06 | 12.62 | |
P/FCF ratio |
9.33 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(9.62) | 7.77 | (8.39) | (15.58) | |
P/B ratio |
3.20 | 5.23 | 6.68 | 20.13 | |
Price to Tangible BV |
3.20 | 5.23 | 6.68 | 20.13 | |
EV/Sales |
0.00 | 3.82 | 2.15 | 6.03 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
2.68 | (4.02) | (1.97) | (4.17) | |
EV/FCF |
2.84 | (3.65) | (1.82) | (3.96) | |
Quick Ratio |
4.83 | 5.78 | 5.81 | 4.47 | |
Current Ratio |
5.12 | 6.06 | 6.15 | 4.73 | |
Net Debt/EBITDA |
6.60 | 7.54 | 7.20 | 6.94 | |
Debt/Assets |
1.49% | 1.32% | 1.49% | 1.67% | |
Debt/Equity |
0.04 | 0.06 | 0.09 | 0.20 | |
Asset Turnover |
0.00 | 0.09 | 0.10 | 0.12 | |
Operating CF/Net income |
1.09 | (1.45) | 1.17 | 0.92 | |
Capex/Depreciation |
1.46 | 2.37 | 0.23 | 1.76 | |
Interest Coverage |
(203.55) | (249.33) | (234.57) | (211.62) | |
Research and Development Expense of Revenue |
327.27% | 371.53% | 357.31% | 296.50% | |
Selling, General and Administrative Expense of Revenue |
158.26% | 225.77% | 172.76% | 152.10% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
52.84% | 65.48% | 46.08% | 39.33% | |
Graham Net Nets |
0.28 | 0.16 | 0.11 | 0.02 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(28.02%) | (30.61%) | (41.21%) | (30.72%) | |
Free Cash Flow Yield |
10.71% | (7.76%) | (11.72%) | (12.05%) | |
Revenue per Share |
0.24 | 0.20 | 0.21 | 0.23 | |
Operating CF per Share |
(0.92) | 1.34 | (0.97) | (0.70) | |
Capex per Share |
(0.03) | (0.03) | 0.00 | (0.01) | |
Free Cash Flow per Share |
(0.95) | 1.31 | (0.97) | (0.71) | |
Cash per Share |
6.27 | 7.61 | 6.55 | 5.84 | |
Shareholders Equity per Share |
2.77 | 1.99 | 1.22 | 0.55 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
2.77 | 1.99 | 1.22 | 0.55 | |
Free Cash Flow |
(83.19) | 114.95 | (85.98) | (63.20) | |
Working Capital |
499.36 | 591.69 | 522.29 | 441.25 | |
Capital Expenditures |
(2.57) | (2.32) | (0.13) | (0.66) | |
Net Current Asset Value |
213.82 | 144.44 | 79.11 | 20.08 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.12 | 0.13 | 0.01 | 0.03 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
17.98 | 5.43 | 29.05 | 7.01 | |
Average Payables |
51.88 | 3.24 | 26.07 | 27.66 | |
Average Assets |
564.11 | 749.26 | 698.16 | 635.11 | |
Average Common Equity |
333.16 | 293.89 | 236.14 | 176.96 |
Columns are period end dates